Hu Gaoxiang
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
IFF to Report Q3 2026 Results on November 3. International Flavors & Fragrances is scheduled to release its third-quarter 2026 earnings on November 3, 2026. This upcoming report is the primary driver of recent attention for the stock. The company's shares have been trading near the upper end of their 52-week range, with an RSI of 75.3 suggesting strong recent momentum ahead of the announcement.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Dana Gets EU Approval For Eaton Mobility Deal. Dana Incorporated has received European Commission approval to acquire Eaton's mobility operations. This regulatory green light is a key step in finalizing the transaction, which aims to expand Dana's presence in the European market. The approval removes a major uncertainty that had been weighing on the deal's timeline.
Transaction History
| BLCO | ▲ Buy | Grant | 20,338 | $0 | 5/27/2025 | View on chart |
| BLCO | ▲ Buy | Grant | 14,696 | $0 | 8/2/2024 | View on chart |
| IFF | ▲ Buy | Option Exercise | 1,671 | $0 | 5/3/2024 | View on chart |
| DAN | ▲ Buy | Option Exercise | 7,982 | $0 | 2/15/2024 | View on chart |
| DAN | ▲ Buy | Option Exercise | 223 | $0 | 2/15/2024 | View on chart |
| IFF | ▲ Buy | Option Exercise | 434 | $0 | 5/4/2023 | View on chart |
| BLCO | ▲ Buy | Grant | 12,857 | $0 | 5/4/2023 | View on chart |
| DAN | ▲ Buy | Option Exercise | 6,578 | $0 | 2/16/2023 | View on chart |
| DAN | ▲ Buy | Option Exercise | 159 | $0 | 2/16/2023 | View on chart |
| BLCO | ▲ Buy | Grant | 13,256 | $0 | 6/28/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
BLCO Advances Oral Dry AMD Treatment After FDA Meeting
Bausch + Lomb reported progress on a new oral drug for dry age‑related macular degeneration after a constructive meeting with the FDA. The company said the discussion helped clarify the regulatory pathway and the drug’s development plan. It also announced that its third‑quarter 2026 earnings will be released on Oct. 28, giving investors a future update on performance.
BLCO Advances Oral Dry AMD Treatment After FDA Meeting. Bausch + Lomb reported progress on a new oral drug for dry age‑related macular degeneration after a constructive meeting with the FDA. The company said the discussion helped clarify the regulatory pathway and the drug’s development plan. It also announced that its third‑quarter 2026 earnings will be released on Oct. 28, giving investors a future update on performance.